Article Per Year (5 Year)
p-Index From 2021 - 2026
0.562
P-Index
This Author published in this journals
All Journal Scientific Journal Jurnal Riset Ilmiah
Rudy Afriant
Universitas Andalas
Biochemistry, Genetics & Molecular Biology Economics, Econometrics & Finance Health Professions Immunology & microbiology Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Public Health Social Sciences Other

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
KARAKTERISTIK KATARAK PADA DIABETES MELITUS DI RSUP DR. M DJAMIL PERIODE 2020-2021 Nada Shafa Salsabila; Kemala Sayuti; Rahmi Lestari; Rudy Afriant; Hendriati Hendriati; Yustini Alioes
SINERGI : Jurnal Riset Ilmiah Vol. 3 No. 2 (2026): SINERGI : Jurnal Riset Ilmiah, February 2026
Publisher : Lembaga Pendidikan dan Penelitian Manggala Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.62335/sinergi.v3i2.2357

Abstract

Cataracts are a condition in which the normally clear and clear lens of the eye turns cloudy. Cataracts that occur due to disorders of the endocrine system are caused by diabetes mellitus. This study aims to determine the characteristics of cataracts in diabetes mellitus at RSUP Dr. M Djamil Padang Period 2020 –2021. This research was a retrospective descriptive study with a cross-sectional approach to determine the characteristics of cataracts in patients with diabetes mellitus at RSUP Dr. M Djamil for the period 2020 - 2021. This study used secondary data in the form of medical records from 39 cataract patients with a history of diabetes mellitus. Data analysis was carried out in the form of descriptive analysis using the SPSS application. This study showed that 28 people (71.8%) respondents aged ≥ 60 years, 24 people were male (61.5%), 30 patients with duration of diabetes mellitus ≥5 years (76.9%), 19 respondents (48.7%) had mature cataracts. Individuals aged ≥ 60 years mostly had mature cataracts (14 people; 50.0%), male respondents mostly had mature cataracts (12 people; 50.0%) and individuals with cataract duration ≥ 5 years mostly had mature cataracts (17 people; 56.7%). The conclusion of this study is the discovery of cataracts in diabetes mellitus with the most age ≥ 60 years, male gender, duration of diabetes mellitus ≥5 years, and type of mature cataract. Most mature cataracts were found at age ≥ 60 years, male gender, and duration of diabetes mellitus ≥5 years.
Hydroxyurea as A Therapeutic Approach in Transfusion-dependent Thalassemia Rudy Afriant; Talsi Transino
Scientific Journal Vol. 5 No. 2 (2026): SCIENA Volume V No 2, March 2026
Publisher : CV. AKBAR PUTRA MANDIRI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56260/sciena.v5i2.343

Abstract

Major thalassemia, or transfusion-dependent thalassemia (TDT), is a severe form of hemoglobin disorder that requires a lifetime regular blood transfusion. Longterm transfusion leads to iron overload that damaging vital organs and increasing morbidity and mortality. Therefore, alternative therapies are needed to reduce transfusion frequency and its complications. Hydroxyurea (HU) is currently being studied for its potential benefit in TDT. Hydroxyurea is an antimetabolite and antineoplastic agent for sickle cell disease. Hydroxyurea induces the production of fetal hemoglobin (HbF) by stimulating γ-globin expression and inhibiting ribonucleotide reductase, which is essential in DNA synthesis, thereby suppressing ineffective erythropoiesis. This pharmacological effect may increase total hemoglobin levels and reduce transfusion requirements in TDT. Hydroxyurea also improves erythropoiesis, decreases ferritin levels, and enhances red blood cell morphology. Meta-analyses indicate that approximately 25–60% of patients experience at least 50% reduction in transfusion needs, with mild and reversible adverse events. While it is not recognized as standard therapy, current studies support the efficacy and safety of hydroxyurea as an adjunctive therapy for TDT, particularly in resource-limited settings in developing countries. Further studies are needed to confirm its long-term safety profile and to identify the patient populations most likely to benefit from this therapy.
Pemberian Antikoagulan pada Kehamilan dengan Risiko Trombosis Rudy Afriant; Zulherman
Scientific Journal Vol. 5 No. 5 (2026): SCIENA Volume V No 5, September2026
Publisher : CV. AKBAR PUTRA MANDIRI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56260/sciena.v5i5.383

Abstract

Tromboemboli vena (TEV) merupakan komplikasi serius yang dapat terjadi selama kehamilan dan masa nifas. Kehamilan secara fisiologis menciptakan keadaan hiperkoagulabel akibat perubahan hemostasis, termasuk peningkatan faktor koagulasi dan penurunan aktivitas fibrinolitik. Kondisi ini meningkatkan risiko TEV sekitar 4–5 kali lipat dibandingkan populasi non-hamil, dengan insidensi tertinggi terjadi pada 6 minggu pertama pascapersalinan. Secara global, kejadian TEV diperkirakan mencapai 1–2 kasus per 1.000 kehamilan. Risiko meningkat signifikan pada wanita dengan trombofilia, riwayat TEV sebelumnya, imobilisasi, obesitas, kehamilan ganda, atau pasca tindakan pembedahan. Antikoagulan merupakan terapi utama untuk pencegahan dan penatalaksanaan TEV dalam kehamilan. Heparin tidak terfraksinasi (UFH) dan low molecular weight heparin (LMWH) merupakan pilihan yang aman karena tidak melintasi plasenta, dengan LMWH lebih disukai karena profil farmakokinetiknya yang stabil dan risiko efek samping lebih rendah. Sebaliknya, warfarin bersifat teratogenik dan DOACs belum direkomendasikan karena keterbatasan data keamanan. Penulisan tinjauan pustaka ini bertujuan memberikan gambaran komprehensif mengenai epidemiologi, faktor risiko, serta prinsip pemilihan dan pemberian antikoagulan selama kehamilan, untuk mendukung pengambilan keputusan klinis yang tepat.
Co-Authors Hendriati, Hendriati Kemala Sayuti Nada Shafa Salsabila Rahmi Lestari Talsi Transino Yustini Alioes Zulherman